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1488Objectives:Malignant hyperthermia susceptibility is an important risk factor during general anesthesia. Affected
patients have an asymptomatic but potentially lethal hypermetabolic reaction after contact with volatile anes-
thetics or succinylcholine. Classic symptoms include hemodynamic instability, combined with acidosis, rigor,
and hyperthermia. During cardiopulmonary bypass, these signs may be obscured, delaying correct diagnosis
and lifesaving treatment. Malignant hyperthermia–susceptible individuals are more sensitive to heat and stress,
so rewarming and catecholamine administration may trigger an episode, necessitating prophylactic measures.
Methods: This systematic review identified typical malignant hyperthermia symptoms during cardiopulmonary
bypass and investigated other factors in cardiac surgery that might trigger an episode in susceptible individuals.
Approaches used to treat and prevent malignant hyperthermia during cardiopulmonary bypass were systemat-
ically analyzed. We conducted a systematic search for reports about malignant hyperthermia and cardiopulmo-
nary bypass. Search terms included malignant hyperthermia and cardiopulmonary bypass, extracorporeal
circulation, or cardiac surgery.
Results: We found 24 case reports and case series including details of 26 patients. In 14 cases, malignant hy-
perthermia crises during or shortly after cardiopulmonary bypass were described. Fourteen reports discussed
prevention of an episode. Early symptoms of a malignant hyperthermia episode include excessive carbon diox-
ide production and metabolic acidosis. Massively increased creatine kinase levels are a strong indicator of a ma-
lignant hyperthermia reaction. Rewarming is associated with development of clinical signs of malignant
hyperthermia.
Conclusions: In potentially susceptible patients, apart from avoiding classic trigger substances, aggressive re-
warming should not be applied. Hemodynamic instability in conjunction with the described symptoms should
result in a diagnostic algorithm. (J Thorac Cardiovasc Surg 2011;141:1488-95)Malignant hyperthermia (MH) remains an important risk
factor during general anesthesia. In initially symptom-free
patients, a potentially lethal hypermetabolic syndrome can
develop after contact with so-called trigger substances,
namely volatile anesthetics (halothane, enflurane, isoflur-
ane, sevoflurane, and desflurane) and succinylcholine
(INN suxamethonium).1-5 The overall incidence of MH is
uncertain, but it is estimated to be between 0.5 to 2 in
100,000 general anesthesia procedures.6-9 The prevalence
of MH susceptibility could be as high as 1 in 3.000 in the
general population.10 Because of the widespread use of vol-
atile anesthetics in cardiac surgery, with or without cardio-
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The Journal of Thoracic and Cardiovascular SurMH primarily affects the calcium homeostasis of skeletal
muscles. Contact with trigger substances leads to a massive
calcium release from the sarcoplasmic reticulum in re-
sponse to a defective ryanodine receptor.1 Increased intra-
cellular calcium levels activate contractile filaments and
stimulate the cellular energy turnover. Dramatic increases
in oxygen consumption and carbon dioxide production are
followed by hugely increased production of lactic acid.11
The ongoing stimulation finally leads to a breakdown of
the cellular metabolism and integrity, and a massive release
of muscle enzymes occurs. Without adequate therapy, mul-
tiorgan failure develops within hours of onset. Dantrolene
blocks the calcium release from the sarcoplasmic reticulum
and allows treatment.12,13
Classic early symptoms of MH episodes include hemo-
dynamic changes to meet the increased oxygen demand.
The expiratory and venous PCO2 values increase, as a result
of a dramatic rise in carbon dioxide production. Lactic ac-
idosis, the eponymous hyperthermia, and a generalized
rigor develop.2 During CPB, these symptoms are often ob-
scured, in part because the MH typical increase of cellular
metabolism may be mitigated by the imposed hypothermia.
InMH-susceptible pigs, temperatures lower than 35Cwere
able to prevent MH episodes completely after exposure togery c June 2011
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
MH ¼ malignant hyperthermia
Metterlein et al Perioperative Managementhalothane and succinylcholine. After systemic rewarming,
the same substances induced a fulminant MH crisis in the
same animals.14 Because of this effect, hypothermia was
even discussed as a treatment option before dantrolene
was available.15
Patients undergoing cardiac surgery often have more sig-
nificant underlying medical conditions than do other surgi-
cal patients. Perioperative complications are therefore
attributed to these underlying problems, and a MH diagno-
sis is thus often delayed or neglected. Timely treatment is
essential, so early symptoms must be identified and inter-
preted appropriately.
Heat and exceptional stress can trigger MH episodes in
susceptible individuals.16 Even if classic trigger substances
are avoided, rapid rewarming and administration of cate-
cholamine might be able to trigger aMH episode. It is there-
fore vital to apply appropriate prophylaxis in patients with
suspected MH susceptibility.
The aim of this systematic review was to identify poten-
tial further cotriggers and early clinical symptoms during
CPB that should prompt further attention. Furthermore, ap-
plied treatment and prophylactic measures are reviewed and
commented on. The purpose is to describe and assess best
practice for adequate management of MH-susceptible car-
diac surgical patients during CPB.P
MMATERIALS AND METHODS
Studies focusing on MH and CPB were systematically searched with
MEDLINE, EMBASE, and the Cochrane Library by 2 authors indepen-
dently (T.M. and P.K.). Any type of report that described CPB in MH-
susceptible individuals or a case of MH in a patient undergoing CPB was
to be included, without language restriction. The free text key words
were malignant hyperthermia or malignant hyperpyrexia or dantrolene
and cardiopulmonary bypass or extracorporeal circulation or cardiac sur-
gery. These were applied in conjunction with the appropriate MeSH terms
(malignant hyperthermia and cardiopulmonary bypass or extracorporeal
circulation).
Titles were evaluated for relevance and further examined if they were in
accordance with the inclusion criteria. In addition, references within the
identified studies were hand searched until no further new trials were iden-
tified. The last electronic search was performed in June 2010. All relevant
articles were retrieved as full-text articles and analyzed in detail.
Data extraction and scoring for validity were performed with estab-
lished procedures.17 Quantitative analysis, or vote counting, was not feasi-
ble because of the lack of appropriate data. All retrieved reports were
tabulated in a spreadsheet and analyzed in a qualitative manner.RESULTS
The systematic search yielded 160 potentially relevant
articles. Of these articles, 136 did not deal with the investi-The Journal of Thoracic and Cargated topic and therefore were not further analyzed. Over-
all, 24 reports met the inclusion criteria and were
included in the analysis (Table 1).18-41
No controlled clinical trial or epidemiologic study deal-
ing with the topic could be found. There were 24 case re-
ports and case series.
Unfortunately, not all case reports gave a detailed de-
scription of underlying medical conditions. Preexisting
neuromuscular symptoms were described in only 1 patient.
A history of cardiomyopathy was documented in only the 2
transplant recipients.Symptoms of MH Episodes
Twelve reports described the development of an episode
of MH in 14 patients (Table 2). In 3 cases, the first symp-
toms occurred during CPB; in the remaining 11 cases,
shortly after CPB. None of the patients had MH typical
symptoms in the prebypass period.
An unexplained increase of the arterial PCO2 was the first
symptom in 11 of the 14 cases. During bypass, only 3 pa-
tients had an elevated arterial PCO2. Within minutes after re-
warming, however, this symptom was present in all
patients. Despite dramatically increased minute ventilation
(up to 40 L/min), values between 44 mm Hg and 67 mm Hg
were documented. Metabolic acidosis was observed during
CPB in only 2 cases. In 6 more cases, metabolic acidosis de-
veloped later (pH between 7.1 and 7.2). Interestingly, hemo-
dynamic instability was considered a symptom of MH in
only 5 patients. Improvement of the hemodynamic situa-
tion, however, was used in 3 of these 5 cases to monitor
the treatment success with dantrolene. A rapid recovery of
the patient’s situation after administration of dantrolene
was considered confirmation of an episode of MH. Rigor,
another classic clinical sign, was observed in only 2 patients
after CPB. In only 3 of the 14 patients with a marked in-
crease in the body temperature was this interpreted as
a sign of an episode of MH. In none of the described cases
was hyperthermia mentioned as the first symptom.
The massive increase of muscle enzymes, resembling
rhabdomolysis, occurred in only 7 of the 14 cases. Creatine
kinase levels ranged from 5000 to 38,000 U/L. Early appro-
priate treatment presumably prevented the development of
rhabdomyolysis in the remaining 7 cases.
In 5 of the analyzed cases, a definite MH diagnosis could
be made with in vitro contracture testing. In the remaining 7
cases, the clinical course and the adequate response to dan-
trolene were considered very strong indicators for an epi-
sode of MH.Treatment of MH Episodes
In a total of 14 cases the treatment was described in detail
(Table 3). The administration of trigger substances (if any
were used) was immediately discontinued in all cases.diovascular Surgery c Volume 141, Number 6 1489
TABLE 1. List of relevant reports
Author(s) Year Type Topic Age (y) Surgery Journal citation
Byrick RJ, et al18 1982 Case report Prophylaxis 54 CABG Can Anaesth Soc J. 1982;29:50-4
MacGillivray RG, et al19 1986 Case report MH crisis 2 Tetralogy of
Fallot correction
Can Anaesth Soc J. 1986;33:509-14
Larach DR, et al20 1987 Case report Prophylaxis 2 VSD correction J Cardiothorac Anesth.
1987;1:448-53
Landymore RW, et al21 1987 Case report MH crisis 54 CABG Can J Surg. 1987;30:209-11
Richardson J22 1987 Case report Prophylaxis 46 CABG Anaesthesia. 1987;42:1125
Marks LF, et al23 1988 Case report Prophylaxis 87 CABG Anaesth Intensive Care.
1988;16:482-5
Kleinman B, et al24 1990 Case series MH crisis 57; 65 CABG; aortic-valve
plus CABG
Cardiothorac Anesth.
1990;4:385-99
Comunale ME, et al25 1991 Case report Prophylaxis 56 CABG J Cardiothorac Vasc Anesth.
1991;5:153-5
Mongan PD, et al26 1992 Case report Prophylaxis 3 ASD correction Can J Anaesth. 1992;39:99-100
Hachenberg T, et al27 1992 Case report Prophylaxis 27 Transplant J Cardiothorac Vasc Anesth.
1992;6:386-7
Quinn RD, et al28 1992 Case report MH crisis 41 Mitral valve Ann Thorac Surg. 1992;53:1114-6
Koehntop DE, et al29 1997 Case report Prophylaxis 14 Transplant Anesth Analg. 1997;85:229-30
Abe K, et al30 1997 Case series MH crisis 64; 69 CABG;
mitral valve
Can J Anaesth. 1997;44:662-5
Allen GC, et al31 1998 Case report MH crisis
with prophylaxis
55 CABG Can J Anaesth. 1989;36:81-5
Lindholm P, et al32 2000 Case report MH crisis 77 Aortic valve
plus CABG
J Cardiothorac Vasc Anesth.
2000;14:576-8
Riess FC, et al33 2001 Case report MH crisis 48 Aortic valve Anesthesiology. 2001;94:355-7
Johi RR, et al34 2003 Case report Prophylaxis 44 CABG Br J Anaesth. 2003;91:744-7
Girard T, et al35 2003 Case report Prophylaxis 55 CABG Acta Anaesthesiol Scand.
2003;47:233-5
Pandya AB, et al36 2003 Case report MH crisis 42 Mitral valve J Cardiothorac Vasc Anesth.
2003;17:625-8
Jonassen AA, et al37 2004 Case report MH crisis 56 Mitral valve
plus CABG
Acta Anaesthesiol Scand.
2004;48:1062-5
Lichtman AD, et al38 2006 Case report MH crisis
with prophylaxis
54 CABG Anesth Analg. 2006;102:372-5
Siddik-Sayyid SM, et al39 2007 Case report Prophylaxis 75 CABG Anesth Analg. 2007;104:214;
author reply, 214-5
Aeschlimann N, et al40 2009 Case report Prophylaxis 58 CABG J Cardiothorac Vasc Anesth.
2009;23:134-5
Firstenberg M, et al41 2010 Case report MH crisis 69 CABG Ann Thorac Surg. 2010;89:947-8
CABG, Coronary artery bypass grafting; MH, malignant hyperthermia; VSD, ventricular septal defect; ASD, atrial septal defect.
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case. That patient died after development of acute renal fail-
ure caused by massive rhabdomyolysis. All other patients
received dantrolene, with dosages ranging from 1.0 to
11.0 mg/kg, and survived the MH episode. The patient
who received a total of 11 mg/kg dantrolene had develop-
ment of a profound muscular weakness that prevented early
extubation. The further clinical course was then compli-
cated by pneumonia in conjunction with prolonged ventila-
tion. In all other cases, no dantrolene-related side effects
were observed. None of the reports mentioned any negative
inotropic effects of dantrolene. To monitor the success of
the causal therapy with dantrolene, both improvement of1490 The Journal of Thoracic and Cardiovascular Surthe hemodynamic instability (3 cases), and decrease of
the measured arterial PCO2 (8 cases) were used.
Additional supportive care was given and included fluid
administration and vasopressors for refractory hypotension.
Low cardiac output was treated with inotropic agents and
mechanical assist devices, such as intra-aortic balloon
pump support. No complications related to the use of cate-
cholamines or inotropic agents were observed in these indi-
viduals. Various antiarrhythmic drugs, including digoxin,
lidocaine, and propranolol, were used to treat arrhythmias.
Among the 7 patients with rhabdomyolysis, only 4 devel-
oped acute renal failure and had to be treated with hemodi-
alysis. One of these 4 patients died (the patient withoutgery c June 2011
TABLE 4. Potential triggers of the MH malignant hyperthermia
episodes in 14 published cases
Trigger No. of cases
Total 14
Volatile anesthetics (halothane,
enflurane, isoflurane, sevoflurane)
10
Succinylcholine 1
Rapid and exaggerated rewarming alone 2
Unknown (possibly enoximone or rewarming) 2
Sums to 15 because 1 patient received both enflurane and succinylcholine.
TABLE 2. Symptoms that occurred during or shortly after
cardiopulmonary bypass, as described in 14 published malignant
hyperthermia episodes
Symptom No. of cases
Total 14
Unexplained increase in arterial PCO2 14
Metabolic acidosis 9
Unexplained hemodynamic instability 5
Rigor 2
Increased serum creatine kinase
and myoglobin levels
7
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Mdantrolene treatment); all others regained sufficient renal
function.
Potential Trigger Substances
In 10 of the 14 described cases, volatile anesthetics as
classic trigger substances were identified (Table 4). In one
of these cases, succinylcholine was used for emergency re-
intubation in the intensive care unit. This patient had an
abortive MH episode develop after administration of enflur-
ane and a fulminantMH crisis after treatment with succinyl-
choline. In 4 cases no classic trigger agents were used.
Rapid and exaggerated rewarming was considered to be
the trigger in 2 of these 4 cases. In 1 case report, enoximone,
a phosphodiesterase III inhibitor, was implicated as trigger.
In that case report, however, no data on the rewarming pro-
cess was presented. In 1 additional case, no trigger could be
identified at all. Again, no information on the rewarming
process was presented.
Prevention of MH Episodes in Known Susceptible
Patients During CPB
A total of 14 reports of cases described measures to pre-
vent an episode of MH in patients known (n ¼ 10) or sus-
pected (n ¼ 4) to be MH susceptible (Table 5). In 12
cases an MH episode was prevented, whereas 2 still had
MH crises develop.
Trigger agents were avoided in all cases, and only decon-
taminated anesthesia machines and oxygenators were used.
Anesthesia was induced and maintained with opiates and
intravenous hypnotics. Relaxation was achieved with non-
depolarizing neuromuscular-blocking agents. DantroleneTABLE 3. Treatment of malignant hyperthermia crisis as described in
14 published case reports
Treatment No. of cases
Total 14
Discontinuation of trigger substances 11
Administration of dantrolene 13
Hemodynamic stabilization with volume
administration, vasopressors, and inotropic agents
11
Antiarrhythmic agents 4
The Journal of Thoracic and Carprophylaxis was applied in 5 cases, with dosages ranging
from 2.0 mg/kg to 6.0 mg/kg. None of the patients who re-
ceived dantrolene showed signs of hypermetabolism. Two
of the 9 patients with suspected MH susceptibility who
had no dantrolene prophylaxis had MH crises develop. In
these 2 cases, no definite trigger could be identified. In
both cases, however, no attention was paid to the rewarming
process. A heat-induced MH episode therefore could not be
excluded. Because of the potential danger, rewarming was
done slowly and stopped at 36C in 3 of the 14 patients.
The aim was to maintain a core temperature under 36C
in the postoperative period. No MH episodes were de-
scribed in any of these cases, even without dantrolene pro-
phylaxis.
One case report even noted avoidance of inotropic agents.
Hypotension and low output were instead treated with vol-
ume substitution and an intra-aortic balloon pump. In all
other cases, inotropic agents were used without reported
problems.
Overall, 17 patients received dantrolene in the perioper-
ative period. A significant muscular weakness developed
in 4 of these patients. Direct negative inotropic effects of
dantrolene were not observed.DISCUSSION
The current systematic review provides evidence that the
nature ofMH episodes observed during CPB does not mark-
edly differ from other MH episodes. The heterogeneous pic-
ture of symptoms present as first signs, however, highlights
the hypothesis that the CPB setting makes an early diagno-
sis and timely treatment more difficult than in other settings.
MH is a potentially lethal disease. The reported outcomes inTABLE 5. Preventive measures in cases of a known or suspected MH
malignant hyperthermia susceptibility, as described in 14 published
cases
Preventive measures No. of cases
Total 14
Avoid contact with trigger substances 14
Slow and careful rewarming 3
Dantrolene 5
Avoid inotropic agents 1
diovascular Surgery c Volume 141, Number 6 1491
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indicating a less severe characteristic of MH during CPB.
Cases with negative outcome may not have been published,
thus creating a significant reporting bias.
Detection of MH by Classic Symptoms
All described cases document that classic MH symptoms
are obscured and can be misinterpreted. It therefore must be
suspected that an episode of MH could even be missed in
some cases because symptoms typical of MH are attributed
to other factors involved in cardiac surgery.
The earliest symptom was an unexplained increase in the
arterial PCO2. Because of a massive increase of the cellular
metabolism in MH, enormous amounts of carbon dioxide
are produced.1 Even an adaptation of the minute ventilation
is often not sufficient to achieve normal values. During
CPB, expiratory PCO2 is not measured. Therefore detection
of this early sensitive sign can be delayed unless frequent
monitoring of the arterial PCO2 takes place and is correlated
with the applied (increased) sweep gas flow.
After depletion of the oxidative reserve, lactic acid is pro-
duced in the muscle. An increase in arterial serum lactate is
seen early duringMH crisis, because the metabolic capacity
of the liver is reduced during an episode of MH.2,42 During
cardiac surgery, periods of impaired tissue oxygenation may
occur, with subsequent development of lactic acidosis. Point
of care measurements for lactic acid would allow a timely
detection of a developing mismatch in oxygenation. A
profound drop in the mixed venous saturation would be
another indication of the massive increase in tissue oxygen
demand.43
Hemodynamic instability is a further classic symptom of
an episode of MH.1 During and right after CPB, however,
patients often undergo periods of arrhythmias and hypoten-
sion. Therefore the hemodynamic situation is not necessar-
ily conducive to diagnosis of MH crisis.
After administration of dantrolene, the hemodynamic situ-
ation usually rapidly improves inMH episodes. This response
can be used to confirm the working diagnosis and to monitor
the success of the treatment.4,44 Because other causes may
contribute to hemodynamic instability, however, clinicians
may not be able to determine the necessary amount of dan-
trolene to administer without a change in the hemodynamic
instability.
Rigor, another classic clinical sign of MH, is often miss-
ing during cardiac surgery. This may be because some
patients receive high amounts of nondepolarizing
neuromuscular-blocking agents. The profound paralysis in-
duced by these agents attenuates the induced rigor without
preventing development of MH.45
For obvious reasons, the eponymous hyperthermia can
only develop after termination of CPB with temperature
control. Inhomogeneous and rapid rewarming can some-
times lead to core body temperatures above 38C, and1492 The Journal of Thoracic and Cardiovascular Surmay therefore be ignored as a symptom of MH. Hyperther-
mia was not the first symptom in any of the described cases.
In fact, in general, hyperthermia is a rather late symptom in
an episode of MH.Metabolic changes, in cardiac patients as
well as in other patient populations, occur earlier and are
more sensitive.11
Another late sign of an episode of MH is the development
of rhabdomyolysis.1 Variable increases of creatine kinase
and myoglobin levels are often seen in surgical patients;
however, above average increases in muscle enzymes
must lead to suspicion of MH. The usefulness of rhabdo-
myolysis as a sign for MH is further impaired by the fact
that various test assays cannot distinguish between myoglo-
bin and hemoglobin. Thus in the postcardiosurgical setting,
a positive test result might be misinterpreted as indicating
hemolysis related to CPB.
In the analyzed cases, MH symptoms occurred either dur-
ing or shortly after CPB. An adequate diagnosis may be
complicated by the delayed onset of MH symptoms. The
initial presentation may even begin in the postoperative pe-
riod. A recent study, however, revealed that so-called ‘‘post-
operative MH’’ is very uncommon (<2% of all cases) and
usually occurs within less than an hour after discontinuation
of the trigger.46
Treatment of Supposed MH Episodes
As a first step in managing a potential MH episode, the
administration of any trigger substances used must
be discontinued immediately. Anesthesia must be main-
tained with intravenous anesthetics and nondepolarizing
neuromuscular-blocking agents.
The only treatment option is dantrolene, which blocks the
calcium release from the sarcoplasmic reticulum by interfer-
ing with the activated type 1 ryanodine receptor. Early treat-
ment of an episode of MH can decrease the mortality from
greater than 80% to less than 5%.2,42 Current guidelines
recommend the administration of 2.5 mg/kg every 5
minutes, until a clinical improvement is seen.2,47 Previous
studies were able to show that no dosing adjustments have
to be made during CPB, because only the initiation of the
CPB leads to a slight decrease in blood levels, as a result of
dilution.47 After administration of 10 mg/kg, without clinical
improvement, a differential diagnosis has to be considered.2,47
Dantrolene can induce a profound muscular weakness by
interfering with the intracellular calcium handling.11 This
side effect should not prevent sufficient treatment, but it
must be considered. Negative inotropic effects were not de-
scribed in the reviewed case reports. In previous animal
studies, however, higher than recommended doses induced
negative inotropic effects.48,49
To improve the hemodynamic situation, supportive care
should be given. Refractory hypotension is treated with vol-
ume administration and vasopressors. Low cardiac output
can be treated with inotropic agents and mechanical assistgery c June 2011
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plications related to the use of inotropic agents have been
documented in MHS-susceptible individuals. Various anti-
arrhythmic drugs can be used to treat arrhythmias. The cur-
rent guidelines advise the use of b-blockers, as described in
the newer case reports.44 Before the acute situation is under
control, separation from CPB should not be recommended,
because both hemodynamics and temperature can easily be
manipulated.
Cardiac surgical patients, in general, have an increased
risk of development of acute renal injury. Additionally, al-
most all untreated MH episodes result in rhabdomyolysis,
with the risk of direct myoglobin-mediated damage to the
kidney.1 An adequate therapy to prevent kidney damage in-
cludes aggressive fluid replacement with crystalloids. Di-
uretics should be used to maintain an adequate urinary
flow. This decreases the risk of myoglobin precipitation
and flushes nephrotoxic agents through the tubules.
Whether osmodiuretics lead to a better outcome than loop
diuretics is unknown. Whether alkalization has a significant
benefit is also not certain. Nephroprotective effects of anti-
oxidants or vitamins could not be demonstrated in larger tri-
als.50 Preventive hemofiltration or hemodialysis does not
show a benefit. Renal replacement therapy should therefore
be initiated according to the clinical routine.2,50
Potential Trigger Agents of MH
All volatile anesthetics and also succinylcholine are consid-
ered classic trigger substances for MH.1,3 Further potential
triggers have been discussed in the literature. Gasoline
vapors and serotonin receptor agonists are considered po-
tential trigger agents.51,52 The role of the body core
temperature in human MH remains controversial. In MH-
susceptible pigs, episodes can be induced by heat alone.11
Physical activity in a hot, humid environment can trigger
MH in human beings.53 Patients with a preexisting fever are
at a higher risk of development of an episode ofMH.Whether
heat itself is capable of triggering MH in human beings is not
known, but the possibility cannot be excluded, and at least
a modulating effect on a developing crisis must be assumed.1
During rapid and exaggerated rewarming, body core temper-
atures above physiologic levels can be reached.
Inotropic agents increase the intracellular calcium level
and are therefore at least theoretically capable of triggering
an episode of MH. In animal studies, however, even ex-
tremely high concentrations of enoximonewere not capable
of triggering a hypermetabolic reaction.54 A modulating ef-
fect of inotropes on a developing MH reaction, however,
cannot be excluded. The calcium sensitizer levosimendan
does not increase the intracellular calcium level,55 so any
influence on cellular calcium handling in MH-susceptible
individuals seems unlikely.
Theoretically, a further trigger is possible, as 4-chloro-m-
cresol, a preservative contained in heparin, can induce inThe Journal of Thoracic and Carvitro a reaction similar to MH.43,56 In MH-susceptible
swine, however, only doses 150-fold higher than those con-
tained in preparations used clinically were able to induce
a reaction in vivo. It therefore seems unlikely that this agent
contributes to the occurrence of MH in human beings.43,57
Prevention of MH Episodes in MH-Susceptible
Patients
Basic preventive measures include the avoidance of trig-
ger substances. The vapor has to be removed, and the tubing
and the carbon dioxide absorber must be renewed. Accord-
ing to various guidelines, the anesthesia machines should be
decontaminated with a high flow of pure oxygen for at least
10 minutes.44 The same measures must be applied to the ox-
ygenator of the CPB circuit.
For induction and maintenance of general anesthesia,
opiates and intravenous hypnotics can be used without
problems. Nondepolarizing neuromuscular-blocking agents
are also considered safe.11
Controversially, preoperative dantrolene prophylaxis has
been discussed; however, MH episodes still occur with dan-
trolene prophylaxis.58 Additionally, early signs ofMH crisis
may be obscured, delaying subsequent treatment. These
limiting factors have to be evaluated critically in light of
the potential side effects of dantrolene.59 Namely, a consid-
erable number of patients treated with dantrolene, espe-
cially those with preexisting neuromuscular disorders,
have relevant muscular weakness develop.60 In our view,
in the 2 cases in which MH episodes occurred despite sus-
pected susceptibility, it is possible that a MH episode could
have been prevented with more attention to the rewarming
process, even without dantrolene prophylaxis. Newer
guidelines no longer recommend the prophylactic adminis-
tration of dantrolene. Appropriate monitoring allows the
early detection of symptoms, and consequent treatment pre-
vents negative outcomes.44
Special attention has to be paid to the rewarming process
because of its potential influence on the body core temper-
ature. Rewarming should be done slowly and stopped at
36C. The aim is to maintain a core temperature of less
than 36C during the postoperative period in MH-
susceptible patients; however, the effects of this mild hypo-
thermia on coagulation must be considered.
Both catecholamines and phosphodiesterase III inhibi-
tors are considered safe drugs. The placement of a complica-
tion-prone mechanical assist device simply to avoid
inotropic agents seems not to be justified by the available
data.
CONCLUSIONS
With the frequent use of volatile anesthetics, MH will re-
main a topic in cardiac anesthesia. Classic symptoms of an
episode of MH are often obscured during CPB. MH as a dif-
ferential diagnosis, however, has to be considered with thediovascular Surgery c Volume 141, Number 6 1493
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Rapid rewarming could play an important role in the devel-
opment of MH episodes and thus may prove a relevant co-
factor in the surgical setting if CPB is applied. Treatment
with dantrolene, the only curative approach, must not be de-
layed. The development of MH episodes in susceptible in-
dividuals, can be avoided with simple interventions.
Anesthesiologists, perfusionists, and cardiac surgeons
must be familiar with these measures, and warning signs
should be added to respective checklists to facilitate early
detection and treatment.
We are grateful to Miss Elise Palmer and Mrs Mantel for proof-
reading the manuscript.
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